Kornimate/medical-research-clean huggingface dataset:
two year study with robotic-arm assisted hip surgery.

Conditions: Surgery; Hip Osteoarthritis

Summary: this study will involve a quantitative assessment of prospectively collected computed tomography, radiographic and patient outcomes data from multiple centers. specifically looking at acetabular cup placement during total hip arthroplasty by either traditional or robotic-arm assisted placement.

the incidence of dislocation following total hip arthroplasty (tha) has been reported to be from 1% to as much as 3.2%. the demand for tha is expected to increase. post- dislocation solutions include closed reduction, open reduction, tha revision, and constrained cup, conversion to hemiarthroplasty, allograft or girdlestone resection. these solutions are often costly, painful and can involve substantial additional risks and complications. acetabular cup placement is an important factor in the stability of the tha. cup malpositioning has been associated with bearing surface ware and dislocation. for most patients, acceptable angles for abduction are 40° abduction (±10°) and 20° (±5°) version. however, malpositioning continues to occur resulting in cup angles outside acceptable ranges and leaving patients with an increased risk of dislocation. this objective of this study is to examine the acetabular cup placement of tha patients and compare results for patients who undergo tha with robotic-arm assistance with those who undergo traditional tha.

Eligibility criteria:
inclusion criteria: 1. patients requiring primary total hip arthroplasty 2. patients willing and able to comply with follow-up requirements 3. patients willing to sign an institutional review board approved informed consent form. exclusion criteria: 1. patients with body mass index \>45 2. patients who are \<18 years of age 3. patients with an active infection or suspected latent infection in or about the hip joint 4. bone stock that is inadequate for support or fixation of the prosthesis 5. previous major hip surgery excluding hip arthroscopy 6. total hip arthroplasty using cement fixation or resurfacing

Keywords: clinical trial randomization hip arthroplasty
perioperative glutamine supplementation and cachexia

Conditions: Glutamine; Metabolic Disorder; Cachexia

Summary: background sarcopenia is characterized by the degenerative loss of skeletal muscle and is associated with increased adverse surgical outcomes. glutamine is considered as an immune-modulating formula, which may stimulate protein synthesis in the skeletal muscle but also inhibited protein-degradation. in this study, the investigators calculate the area and volume psoas major muscle (pmma; pmmv) of the third lumbar vertebral body as the reference of skeletal muscle. the aim of this study is to investigate whether perioperative glutamine supplementation restores atrophy of psoas muscle.

a total of 550 gastric adenocarcinoma (ga) patients undergoing gastrectomy were enrolled for the study. computed tomography was used to assess the short axis of the psoas muscle, and the change was calculated between preoperative day and three months after gastrectomy. perioperative glutamine supplementation (pgs) was defined as the subjects with five-day parenteral plus one-month oral use. a linear regression model was performed to predict this association by adjusting clinic-demographics and nutritional calories.

Eligibility criteria:
inclusion criteria: * gastric cancer patients undergoing gastrectomy exclusion criteria: * hepatic or renal failures

Keywords: gastric cancer cachexia psoas muscle glutamine
fluvastatin ameliorates atherosclerosis study

Conditions: Coronary Heart Disease; Atherosclerosis

Summary: the study is designed to assess the effect of statin on atherosclesrosis progression as well as to explore its potential mechanism besides lipid modifying , such as effect on inflammation and vascular calcification.

carotid imt has been used in various studies (e.g. asap, arbiter, meteor) and is well accepted as a valid surrogate marker for atherosclerosis. the thickness of cimt is significantly associated with the presence and the extent of coronary disease. slower progression of atherosclerosis as measured by carotid ultrasound is also associated with a lower risk of nonfatal mi. in a meta analysis, for every 0.0 1-mm-per-year decrease in carotid imt, there was a significant 18% reduction in the risk of nonfatal mi. measurement of carotid imt carries the advantage of being non-invasive and easy to use with a good degree of reproducibility. statins have been shown to slow the progression of atherosclerosis or even to induce regression of atherosclerosis. change of carotid imt by statins have been found to correlate with the extent of ldl-c reduction and hdl-c increase however non-lipid effects (e.g. effects on inflammation, calcification ) may also play a role in the beneficial effects of statins on atherosclerosis.osteopontin (opn), an acidic phosphoprotein, and osteoprotegerin (opg), a member of the tumor necrosis factor-a receptor superfamily, have been recently demonstrated to modulate vascular calcification. recent studies have shown an association of serum opn and opg levels with cardiovascular diseases and vulnerable carotid plaque .

Eligibility criteria:
inclusion criteria: 1. newly diagnosed coronary heart disease 2. one or more maximum imt measurements of ≥1.1mm. 3. age 45 to 70 years old 4. ldl-c≥130mg/dl 5. not receiving regular lipid lowering treatment 6. written informed consent exclusion criteria: 1. myocardial infarction as the first symptoms of coronary heart disease 2. patients with known hypersensitivity to fluvastatin or any of the excipients 3. pregnancy or lactation, or women of childbearing potential not using effective contraception 4. known muscle disease or history of muscle disease (e.g. myopathy, myositis, rhabdomyolysis) and/or serum ck levels greater than 2 x upper limit of normal (uln) 5. renal dysfunction 6. active liver disease and/or serum transaminase levels (alt, ast) greater than 2x uln 7. any conditions the investigator consider not suitable for long-term follow up

Keywords: statin atherosclerosis coronary heart disease opn opg
the pk characteristics of the co-administration of rosuvastatin and telmisartan/amlodipine and jlp-1401 in healthy adult volunteers volunteers

Conditions: Hypertension With Dyslipidemia

Summary: the pk characteristics of the co-administration of rosuvastatin and telmisartan/amlodipine and jlp-1401 in healthy adult volunteers.


Eligibility criteria:
inclusion criteria: * healthy male volunteer, age is over 19 years body weight is over 55kg, the result of body mass index(bmi) is not less than 17.5 kg/m2 , no more than 30.5 kg/m2 * subject who has the ability to comprehend the study objectives, contents and the property of the study drug before participating in the trial * subject who has the ability and willingness to participate the whole period of trial exclusion criteria: * presence of medical history or a concurrent disease that may interfere with treatment and safety assessment or completion of this clinical study, including clinically significant disorders in kidney, liver, cardiovascular system, respiratory system, endocrine system, or neuropsychiatric system. * subjects who are allergic to investigational drug. * subjects who have a medical history which can affect the clinical trial. * sbp \ 140mmhg or dbp \ 100mmhg * ast or alt \> x 2 unl * ck \> x 2 unl * history of drug abuse or positive drug screening. * participation in other drug studies within 3 months prior to the drug administration. * whole blood donation within 60 days, blood component donation within 30 days or who got transfusion within 30days.
hla-dq2-gliadin tetramer for diagnosis of celiac disease

Conditions: Celiac Disease; Gluten

Summary: the investigators will evaluate the use of an hla-dq2-gliadin tetramer for staining of gluten specific t cells in the diagnostics of uncertain celiac disease. some patients have started on a gluten free diet without a diagnosis of celiac disease. subsequent later investigation in special care is difficult as the patients often are reluctant to prolonged gluten challenge. the investigators use the hla-dq2-gliadin tetramers for detection of gluten specific t cells after a short gluten challenge. by this method the investigators search to discriminate between true celiac disease and clinical gluten intolerance without celiac disease, in a population of hla-dq2+ persons already on a gluten free diet without a formal diagnosis of celiac disease.


Eligibility criteria:
inclusion criteria: * hla-dq2+ celiacs and hla-dq2+ persons who have been on a gluten free diet for at least 4 weeks. exclusion criteria:pregnancy * other severe disease * refusal to participate * hla-dq2 negativity

Keywords: celiac disease. food intolerance. gluten intolerance without celiac disease.
quality of life following gastric bypass surgery.

Conditions: Obesity

Summary: a central goal of health care is to maximize patient functioning and well-being. this has prompted measurement of health-related quality of life (hrqol) that encompasses physical, psychological, and social functioning. while obese people have generally impaired hrqol, people seeking bariatric surgery for obesity appear to have poorer hrqol than obese individuals seeking non-surgical treatment or obese individuals not seeking weight-loss treatment. hrqol improves significantly after bariatric surgery, but often with large individual variations in outcome. as gastric bypass is an invasive procedure with irreversible influences on eating behaviour and possible serious adverse events, it is important to identify potential risk factors for a poorer long-term result. in denmark, bariatric surgery is free of charge for patients fulfilling the danish health and medicines authority guidelines, which until 2011 were in line with international guidelines. however, in 2011 access to surgery was dramatically restricted and the annual number of operations reduced from 0.9 per 1000 inhabitants (2010) to 0.2 per 1000 inhabitants (2012). the restrictions involved a tightening of the criteria for patients without manifest obesity comorbidities, raising lower body mass index (bmi) threshold from 40 to 50 and increasing the lower age limit from 18 to 25 years (11). it is not known whether patients fulfilling the tighter criteria benefit more from surgery than patients who only met the previous criteria. this study assessed hrqol changes associated with roux-en-y gastric bypass with follow-up over an average of 22 months. the aim was to explore whether postoperative hrqol variations were associated with identifiable socio-demographic or clinical characteristics. in particular, whether hrqol changes differed for patients fulfilling the current danish criteria and patients only fulfilling the previous criteria.


Eligibility criteria:
inclusion criteria: * patients referred for gastric bypass. exclusion criteria: * patients who did not fulfill the national criteria.

Keywords: gastric bypass health-related quality of life sf-36 questionnaire treatment guidelines
cough suppressive therapy in patients with chronic cough

Conditions: Chronic Cough

Summary: in this randomized, placebo-controlled, interventional study on chronic cough a non-pharmacological cough suppressive therapy is the intervention to be studied, with a control group receiving treatment consisting of general healthy lifestyle advice. the following data will be collected before, after and up to six months after treatment: standardized questionnaires for diagnosis of background factors, leicester cough questionnaire (lcq), work ability index (wai), and cough frequency as well as lung function and biomarkers. the primary treatment effect measurement will be changes in chronic cough-related quality of life, measured by the leicester cough questionnaire (lcq).

the study will be carried out in collaboration between respiratory physicians, clinical physiologists, physiotherapists, speech- and language therapists and gastroenterologists. the primary hypothesis of the planned study is: the cough suppressive therapy improves chronic cough-related quality of life and work ability, and is sustained over six months after treatment. the secondary hypotheses of the planned study are: treatment of chronic cough by the cough suppressive therapy can reduce cough frequency (measured by an automated cough detector), airway inflammation and airway resistance. baseline differences in clinical findings, biomarkers and physiologic measurements predict different treatment effects. the following data will be collected before and after treatment: * standardized questionnaires for diagnosis of background factors and cough duration, lcq, wai, questions on sick leave days, voice disturbance questionnaire. * physiological measurements: spirometry with reversibility test, impulse oscillometry before and after provocation with hypertonic saline inhalation. 24 hours cough frequency analysis, voice analysis. * biomarkers: fractional exhaled nitric oxide (feno), blood-eosinophils and eosinophil cationic protein in serum, proteomics in particles in exhaled air (pexa)

Eligibility criteria:
inclusion criteria: * chronic cough (duration \>2 months) without a structural lung disease and a normal chest x-ray, which have failed pharmacological treatment. * being able to understand the swedish language. exclusion criteria: * pulmonary abnormalities on a chest x-ray, structural lung disease, or chronic obstructive pulmonary disease (copd) of spirometry stage global initiative for obstructive lung disease (gold) 2 or higher. * smoking under the last three months. * ongoing or recent treatment with angiotensin-converting enzyme (ace) inhibitor * active aspiration, vocal cord nodules or upper respiratory tract infection in the previous 4 weeks.
development of an arabic central auditory processing remediation program for dyslexic children with(c)apd

Conditions: Central Auditory Processing Disorder; Dyslexia

Summary: rehabilitation of dyslexic children with (cental) auditory processing disorder. the first group will receive the proposed program the arabic version of differential processing training program and the control group will receive the computer based auditory traing program (cbat).

central auditory processing disorder(c)apd is defined as difficulty for children with normal hearing to listen selectively in the presence of noise, to combine information from two ears properly, to process speech when it is slightly degraded, and to integrate auditory information when it is delivered faster than the individual with (c)apd can process.( the estimated prevalence of (c)apd in the school-aged population is approximately 2 to 5 %, and the estimated prevalence of (c)apd in the older adult population is 76 %. these percentages are higher than those affected by hearing loss. dyslexia and (c)apd are common comorbidities and since there is limited research on (c)apd within each related academic discipline. furthermore the language, audiologiological , and cognitive nature of the disorder confirmed that a multi-disciplinary effort is needed in order to provide clinical decision and effective intervention for the (c)apd population. hence development of additional intervention tools for use in clinics, schools and home settings is warranted . the aim of this work is to develop a novel arabic (c)apd remediation program ,to study the outcome of the program and to validate it's effectiveness by comparing it to the arabic computer based auditory training(cbat) program.

Eligibility criteria:
inclusion criteria: 1. dyslexic children with (c)apd 2. age from 6-12 years. 3. no gender limit. 4. normal peripheral hearing i.e pure tone averages (average threshold from 250to 8000 hz) should be less than or equal 25db hearing level bilaterally. 5. normal speech audiometry results. 6. normal results on immitancemetry. 7. average or below average iq. 8. normal language development. exclusion criteria: 1. adhd subjects. 2. associated neurological and psychiatric disorders. -
thrombocytopoiesis and platelet homeostasis in infants with bronchoplumonary dysplasia

Conditions: Bronchopulmonary Dysplasia; Thrombocytopenia; Preterm Infant

Summary: to investigate the relationship between bronchopulmonary dysplasia and thrombocytopenia.

a prosepective case-control study ,the case were matched with 1:1according to gestational age,birth weight and admission diagnosis and divided into two groups according to the consensus definition of national institute of child health and human development (nichd). platelet count, circulating megakaryocyte count, platelet activating markers (cd62p and cd63), thrombopoietin were recorded and compared in two groups, then, serial thrombopoietin levels and concomitant platelet counts were measured in infants with bpd.

Eligibility criteria:
inclusion criteria: 1. presence of clinical and radiologic signs of bpd, according to conventional criteria (greenough, 1992); 2. presence of peripheral arterial catheter; 3. gestation \<32 weeks; 4. birth weight \<1.5 kg; 5. requiring mechanical ventilation for the treatment of respiratory distress syndrome for at least 3 days during the first weeks of life; 6. ventilator and/or oxygen dependent at time of enrolment; exclusion criteria: 1. congenital abnormalities; 2. infection (bacteria infection confirmed by positive blood culture or viral infection confirmed by serological test or viral culture) 3. evidence of complications of perinatal asphyxia including an apgar score \<3 at one or five minute after birth, evidence of hypoxic-ischemic encephalopathy, acute tubular necrosis, or transient myocardial ischemia; 4. identifiable hematologic disease;
percutaneous mitral valve repair in cardiogenic shock: mitra-shock study

Conditions: Mitral Regurgitation Functional

Summary: cardiogenic shock (cs) is a medical emergency and a frequent cause of death. cs can be complicated and/or precipitated by mitral regurgitation (mr). the efficacy of percutaneous treatment of mr in patients with cardiogenic shock is unknown. the aims of the study will be to analyse the efficacy of mitraclip therapy on early (30 days) and midterm mortality (6 months) as well as the predictors of outcomes. investigators will also report the rate of periprocedural complications such as minor and major bleeding, vessel injury and acute kidney injury (aki). it is a multicenter retrospective observational study on ce marked medical device (mitraclip® system). retrospective time range: from 01/01/2012 to 01/01/2020


Eligibility criteria:
inclusion criteria: * older than 18 years old exclusion criteria: * multiorgan failure, * va-ecmo, * inadequate peripheral access because of vascular disease, * not suitable mitral valve anatomy.
rct on the efficacy of methotrexate for the prevention of gtd

Conditions: Hydatidiform Mole

Summary: a randomized, controlled trial to evaluate the efficacy of methotrexate for the prevention of postmolar gestational trophoblastic disease among patients with high-risk hydatidiform mole.

a randomized, controlled trial to evaluate the efficacy of methotrexate for the prevention of postmolar gestational trophoblastic disease among patients with high-risk hydatidiform mole. women who will undergo suction curettage for complete hydatidiform mole at the philippine general hospital, who are at risk for developing postmolar gestational trophoblastic disease will be included in the study. patients will receive either a single course of methotrexate or vitamin b complex (benutrex) within fourteen days from molar evacuation. patients' serum beta hcg will be monitored 1 week after molar evacuation and then every 2 weeks until the titers become normal for three consecutive determinations, then monthly for 6 months (every 2 months for the next 6 months).

Eligibility criteria:
inclusion criteria: * diagnosis and molar evacuation done at the department of obstetrics and gynecology of the philippine general hospital; * patients who will undergo suction curettage for evacuation of molar pregnancy; * histopathologically confirmed complete hydatidiform mole; * must have at least one of the following risk factors for the development of postmolar gestational trophoblastic disease: * uterine size larger than age of gestation of more than 6 weeks * serum b-hcg titer more than or equal to 100,000 mlu/ml * theca lutein cysts more than or equal to 6 cms in size * gravidity of 4 or more * recurrent molar pregnancy * medical complications arising from trophoblastic proliferation such as dic, pre-eclampsia, thyrotoxicosis, pulmonary insufficiency * complete data; * patient must have at least one year of regular follow-up and hcg monitoring following onset of remission; * should have signed the consent form. exclusion criteria: * patients who are lost to follow-up or with incomplete data * patients who underwent total hysterectomy for evacuation of molar pregnancy * patients who are unable to complete the methotrexate treatment * patients who get pregnant within a year following remission * patients with a previous history of gestational trophoblastic neoplasia * patients with medical problems/complications that inhibit administration of methotrexate

Keywords: postmolar gestational trophoblastic disease, hydatidiform mole
current practices of upper limb rehabilitation after stroke

Conditions: Stroke; Upper Extremity Paresis; Survey

Summary: a survey was conducted among physiotherapists and occupational therapists working with stroke patients. the survey consisted out of 30 questions enquiring personal information and upper limb specific topics divided in 3 sections: (1) passive mobilization, (2) active exercises and (3) immobilization. the survey took approximately 20 to 30 minutes to complete. the survey for stroke survivors was divided in seven sections: (1) personal information (2) motor recovery of the upper limb and expectations on upper limb recovery; (3) comfort, pain and quality of life (qol); (4) immobilization ; (5) physiotherapy; (6) occupational therapy; (7) nursing (only for patients less than 6 months after stroke). the length to complete the survey was also organized to be achieved in 20 to 30 minutes.


Eligibility criteria:
stroke patients inclusion criteria: * stroke with upper limb paresis exclusion criteria: * severe language or cognitive problems which make it impossible to complete the survey therapists inclusion criteria: * physiotherapists * occupational therapists * experienced in the treatment of stroke patients